Improving the accuracy of cancer biomarker testing using advanced imaging techniques
Official title: Reproducible and Accurate PD-L1 Immunohistochemistry Biomarker Quantification Using Virtual Multiplex Immunofluorescence Restaining
Funded at Sloan-Kettering Inst Can Research · NIH-11018883 · Data updated 2026-11-12
This study is looking at a new way to check for a protein called PD-L1 in cancer patients to help doctors decide who might benefit from immunotherapy, making sure that patients get the right treatment without wasting money on options that won't work for them.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | December 1, 2024 |
| Project end | November 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $683,089 |
| NIH project number | 1R37CA295658-01 |
| Project ID | NIH-11018883 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are cancer patients being considered for immunotherapy who require accurate PD-L1 expression assessment.
✕Less likely to help
Patients who do not have cancer or those whose treatment does not involve immunotherapy may not benefit from this research.
What this research studies
This research focuses on enhancing the assessment of PD-L1 protein expression in cancer patients, which is crucial for determining their eligibility for immunotherapy treatments. By utilizing advanced multiplex immunofluorescence staining techniques, the study aims to provide more accurate and reproducible results compared to traditional methods. This approach seeks to reduce the variability in scoring by pathologists, thereby ensuring that patients receive appropriate treatment based on reliable biomarker evaluations. The goal is to identify patients who are unlikely to benefit from expensive immunotherapy, ultimately improving treatment outcomes and reducing unnecessary costs.
Why it matters
Potential benefit: If successful, this research could lead to more precise patient selection for immunotherapy, improving treatment efficacy and reducing healthcare costs.
How similar studies have gone: Previous research has shown promising results with multiplex immunofluorescence techniques, indicating potential for significant advancements in biomarker quantification.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Nadeem, Saad — Sloan-Kettering Inst Can Research
- Study coordinator: Nadeem, Saad
Related research
Other NIH-funded projects on the same topics.
-
Understand how skeletal muscle nuclei specialize and arrange themselves for proper muscle function
A study to uncover how the hundreds of nuclei in skeletal muscle fibers acquire different roles and positions to keep muscles strong and healthy.
-
Genomic profiling and outcomes of cancers in World Trade Center-exposed survivors and responders
This project looks at the genetic makeup and real-world cancer outcomes in people exposed to the World Trade Center disaster to understand how their cancers behave and respond to treatments.
-
Meaning-Centered Psychotherapy for Mexican Patients with Advanced Cancer
A cancer center in Mexico will test a culturally adapted therapy to help Mexican patients with advanced cancer find meaning, peace, and purpose at the end of life.
-
High-specificity genome-scale cell-surface proteomics to find tumor targets
A cancer research project is trying to map all the proteins on the surface of ultra-rare sarcoma cells to find safe, targeted ways to treat them.
-
Priorities for testing and choosing combination therapies in rhabdoid tumors to guide clinical trials
A coordinated, multi-site effort will rigorously test promising drug combinations in rhabdoid tumors to identify the most promising options for future patient trials.
-
ecDNA in Cancer: Understanding and targeting circular DNA that drives tumor growth
A cancer-focused project to understand how extrachromosomal DNA helps tumors grow and resist treatment, and to develop new ways to target these mechanisms.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.